Nextblockbuster, excellent link and thanks to F6. F6 comes up with some great digging and this was very helpful.

A few observations;

1. P5 - I am amazed at the median upfront payments. At phase 3 it is only $25 million. The article does state that the range of deals is very wide. I must have been wrong in my interpretation.
2. It emphasizes having alternatives as a key negotiating platform. Do we have any, none the less alternatives?
3. P9 - States that a compound with multiple compounds has a better negotiating platform. Apabetalone fits this criteria.
4. It states that BPs typically have 500 to 1,000 companies/drugs they are vetting and that gets reduced to a very small level before serious analysis begins. Don has indicated that RVX is in regular contact with BPs but he also admitted it is very difficult to get an audience with top executives. Perhaps this means that BP executives have vetted down their targets and RVX and Zenith are not on their lists at this stage.
5. It discusses the need for a virtual data room and discusses who should be present to answer questions and says the CEO should not be involved at that stage. Agreed. I don't think Don would be a help.

I guess the bottom line is that it a tough row to hoe and we have a very long journey ahead.

So what I would love to see is for me to be proven wrong shortly if Don announces a new partner with both geographic, scientific and royalalty assets.

DYODD        GLTA - we'll need it.

Cheers

Toinv